NCT06383091 Impact of Manual Therapy on Laryngeal Function Following Total Thyroidectomy
| NCT ID | NCT06383091 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Johns Hopkins University |
| Condition | Total Thyroidectomy |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2024-06-03 |
| Primary Completion | 2027-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2024-06-03 with a primary completion date of 2027-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In this clinical trial, the investigators are seeking to learn if a course of voice therapy, including neck massage, stretches and pain science education in addition to voice exercise and scar massage will effectively treatment patient complaints of swallowing or voice changes after total thyroidectomy as compared to voice exercise and scar massage alone. The main questions it aims to answer are: Will neck massage, stretches and pain science education reduce patient complaints of swallowing changes after total thyroidectomy? Will neck massage, stretches and pain science education reduce patient complaints of voice changes after total thyroidectomy? Will neck massage, stretches and pain science education reduce patient complaints of scar tethering and quality changes after total thyroidectomy? Will neck massage, stretches and pain science education improve quality of life after total thyroidectomy? Participants will: Participate in 4 visits with the participant's endocrine/laryngology surgeon. One prior and 3 after surgery for endoscopic evaluation and tests. Participate in 5 Speech-Language Pathology Sessions for intervention exercises and tests. One prior and 4 after surgery. Complete a journal of the participant's Home Exercise Practice
Eligibility Criteria
Inclusion Criteria: * The study population consists of individuals with malignant or benign thyroid disease scheduled to undergo total thyroidectomy * native speakers of English * All patients will be greater than or equal to 18 years of age Exclusion Criteria: * Participants will be excluded if they have completed voice therapy prior * are current smokers * have organic vocal fold pathology or clear mucosal changes to the vocal folds that can affect vibration (e.g., vocal fold scar, polyp, or nodules), * pre-existing unilateral or bilateral vocal fold paralysis * have had prior surgical neck or chest history including central or lateral neck dissection * pre- or post-operative abscess or inflammation * have a history of head, neck, or chest radiation, diagnosed baseline oral or pharyngeal dysphagia * have recently started taking in the last 3 months, plan to start taking or increase the level of testosterone during the treatment period * greater than 10% otherwise unexplained weight loss * had a recent aspiration pneumonia
Contact & Investigator
Vaninder Dhillon, MD
PRINCIPAL INVESTIGATOR
Johns Hopkins University
Frequently Asked Questions
Who can join the NCT06383091 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Total Thyroidectomy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06383091 currently recruiting?
Yes, NCT06383091 is actively recruiting participants. Contact the research team at Cligon4@jhmi.edu for enrollment information.
Where is the NCT06383091 trial being conducted?
This trial is being conducted at Baltimore, United States, Bethesda, United States.
Who is sponsoring the NCT06383091 clinical trial?
NCT06383091 is sponsored by Johns Hopkins University. The principal investigator is Vaninder Dhillon, MD at Johns Hopkins University. The trial plans to enroll 20 participants.